Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

For further information please contact: Verona P Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Verona Pharma Option Volume And Open Interest ... The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease ...

Verona Pharma (NASDAQ:VRNA – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $60.00 price target ...

Verona Pharma plc (NASDAQ ... Secondly, the company’s strategic projects like Ensifentrine hold future potential for investors. It is a first-in-class dual inhibitor of PDE3 and PDE4, targeting ...

Roth Mkm started coverage on shares of Verona Pharma (NASDAQ:VRNA – Free Report) in a report released on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $68.00 price ...

H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.